Literature DB >> 2495039

Some characteristics of aggregates of IgG and plasma proteins in heat-treated factor VIII concentrates.

C Wadsworth1, L A Hanson, H Kjellman, T Söderström, M Blombäck.   

Abstract

Eight batches of commercial heat-treated and one untreated factor VIII concentrate from 6 producers were analyzed for their content of IgG, IgG subclasses, IgG aggregates and the presence of other plasma proteins combined with the IgG as well as for anticomplement activity. Methods used were thin-layer gel filtration, immuno-gel filtration, spot immuno-precipitate assay in a double antibody version and an agarose plate haemolysis inhibition assay of complement fixation. The IgG content varied from 0.1-6.90 g/l. In all preparations IgG existed as monomers and aggregates. Associated with the IgG were also found, at significantly increased amounts compared to normal serum and intravenous immunoglobulin, one to four of the following plasma proteins; fibronectin, fibrinogen, von Willebrand factor antigen, Clq, albumin and IgA. Three batches from two producers had high anticomplementary activity, presumably caused by the IgG aggregates. Two of these deviated strikingly from normal human serum pools in percent distribution of IgG subclasses. It is hypothesized that these aggregates can induce side effects or cause immunological aberrations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495039     DOI: 10.1007/bf00320432

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  36 in total

1.  T lymphocytes from hemophiliacs proliferate after exposure to factor VIII product.

Authors:  D S Matheson; B J Green; M C Poon; T J Bowen; M J Fritzler; D I Hoar
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144

2.  Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura.

Authors:  J F Delfraissy; G Tchernia; Y Laurian; C Wallon; P Galanaud; J Dormont
Journal:  Br J Haematol       Date:  1985-06       Impact factor: 6.998

3.  Modulation of the immune response by immunoglobulin for intravenous use. II. Inhibitory effects of sera from treated patients.

Authors:  W Stohl; C Cunningham-Rundles; C Thompson; L Mayer
Journal:  Clin Immunol Immunopathol       Date:  1986-11

4.  [Side-effects of factor VIII substitution in patients with hemophilia A (author's transl)].

Authors:  V Tilsner; H Reuter
Journal:  MMW Munch Med Wochenschr       Date:  1982-06-04

5.  Spectrum of HTLV-III infection in a hemophilic cohort treated with blood products from a single manufacturer.

Authors:  K M McGrath; D Spelman; M Barnett; S Kellner
Journal:  Am J Hematol       Date:  1986-11       Impact factor: 10.047

6.  Human T-lymphotropic virus type III (HTLV-III) infection in seronegative haemophiliacs after transfusion of factor VIII.

Authors:  C A Ludlam; J Tucker; C M Steel; R S Tedder; R Cheingsong-Popov; R A Weiss; D B McClelland; I Philp; R J Prescott
Journal:  Lancet       Date:  1985-08-03       Impact factor: 79.321

7.  A longitudinal immunologic evaluation of hemophiliac patients.

Authors:  R D deShazo; C B Daul; W A Andes; B E Bozelka
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

8.  Clinical tolerance and catabolism of plasmin-treated gamma-globulin for intravenous application.

Authors:  S Barandun; V Castel; M F Makula; A Morell; R Plan; F Skvaril
Journal:  Vox Sang       Date:  1975       Impact factor: 2.144

9.  Cause of death in hemophilia A patients in the United States from 1968 to 1979.

Authors:  D L Aronson
Journal:  Am J Hematol       Date:  1988-01       Impact factor: 10.047

10.  Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates.

Authors:  C M Heldebrant; E D Gomperts; C K Kasper; J S McDougal; A E Friedman; D S Hwang; E Muchmore; S Jordan; R Miller; E Sergis-Davenport
Journal:  Transfusion       Date:  1985 Nov-Dec       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.